Abciximab or eptifibatide: Differences in outcomes of patients treated with abciximab versus eptifibatide as adjunct therapy for primary percutaneous coronary interventions for ST elevation myocardial infarction.

被引:0
|
作者
Hitinder, Gurm [1 ]
Share, David [1 ]
Smith, Dean E. [1 ]
LaLonde, Thomas [1 ]
O'Donnell, Michael [1 ]
Riba, Arthur [1 ]
Changezi, Hameem [1 ]
Zughaib, Marcel [1 ]
Chandra, Harish [1 ]
Safian, Robert [1 ]
Moscucci, Mauro [1 ]
机构
[1] Univ Michigan, Med Ctr, Ann Arbor, MI 48109 USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:292A / 292A
页数:1
相关论文
共 50 条
  • [1] Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions
    Midei, Mark G.
    Coombs, Vicki J.
    Lowry, David R.
    Drossner, Michael N.
    Prewitt, Kerry C.
    Wang, John C.
    Loughrey, Michele B.
    Gottlieb, Sidney O.
    CARDIOLOGY, 2007, 107 (03) : 172 - 177
  • [2] Eptifibatide and abciximab are equivalent as adjunctive therapy for percutaneous coronary intervention in a large unselected population with ST elevation myocardial infarction.
    Raveendran, G
    Lennon, R
    Bell, M
    Bresnahan, J
    Gersh, B
    Holmes, D
    Mathew, V
    Singh, M
    Ting, H
    Rihal, C
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 38E - 38E
  • [3] Comparison by Meta-Analysis of Eptifibatide and Tirofiban to Abciximab in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
    Ottani, Filippo
    La Vecchia, Luigi
    De Vita, Maria
    Catapano, Ottorino
    Tarantino, Fabio
    Galvani, Marcello
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (02): : 167 - 174
  • [4] Eptifibatide versus abciximab in primary PCI for acute ST elevation myocardial infarction. The randomized EVA-AMI Study
    Zeymer, Uwe
    Teiger, Emmanuel
    CIRCULATION, 2007, 116 (22) : 2628 - 2628
  • [5] Eptifibatide and Abciximab are associated with similar outcomes when used during Primary Percutaneous Coronary Intervention for ST-elevation myocardial infarction
    Ding, Nicola
    Jones, Daniel A.
    Peterzan, Mark
    Gallagher, Sean
    Antoniou, Sotiris
    Wright, Paul
    Rathod, Krishnaraj
    Jain, Ajay
    Knight, Charles
    Mathur, Anthony
    Weerackody, Roshan
    Wragg, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (18) : B48 - B48
  • [6] Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention
    Coons, JC
    Seybert, AL
    Saul, MI
    Kirisci, L
    Kane-Gill, SL
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (10) : 1621 - 1626
  • [7] Eptifibatide and abciximab are associated with similar outcomes when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction
    Akhtar, M. M.
    Jones, D. A.
    Ding, N.
    Gallagher, S.
    Rathod, K. S.
    Jain, A.
    Knight, C.
    Mathur, A.
    Weerackody, R.
    Wragg, A.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1024 - 1025
  • [8] Comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary interventions
    Changezi, H
    Schweiger, MJ
    Prescod, D
    Cook, JR
    CIRCULATION, 1999, 100 (18) : 187 - 187
  • [9] Clinical outcomes comparing eptifibatide and abciximab in ST-elevation acute myocardial infarction patients undergoing percutaneous coronary intervention.
    Midei, MG
    Lowry, DR
    Coombs, V
    Loughrey, MB
    Gottlieb, SO
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (6A): : 240E - 241E
  • [10] Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction
    Raveendran, Ganesh
    Ting, Henry H.
    Best, Patricia J.
    Holmes, David R., Jr.
    Lennon, Ryan J.
    Singh, Mandeep
    Bell, Malcolm R.
    Long, Kirsten Hall
    Rihal, Charanjit S.
    MAYO CLINIC PROCEEDINGS, 2007, 82 (02) : 196 - 202